Literature DB >> 14770052

Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included.

Mark Zimmerman1, Iwona Chelminski, Michael A Posternak.   

Abstract

The inclusion and exclusion criteria used to select subjects for participation in antidepressant efficacy trials (AETs) vary from study to study. It is unknown how much impact different sets of exclusion criteria have on the representativeness of subjects treated in AETs. In the present study, we applied the inclusion and exclusion criteria used in 39 recently published AETs to patients evaluated in routine clinical practice to evaluate the range and extent of the representativeness of samples treated in AETs. Nearly 600 patients with DSM-IV major depressive disorder (MDD) or bipolar depression underwent a thorough diagnostic evaluation. Inclusion and exclusion criteria used in AETs were applied to determine how many patients from our sample would have qualified for each AET had they applied. Approximately one sixth of the 596 depressed patients would have been excluded from an efficacy trial because they had a bipolar or psychotic subtype of depression. In the remaining 503 outpatients with nonpsychotic, unipolar MDD, the rates of exclusion ranged from 0% to 95.0% (mean=65.8%). Thus, the findings suggest that there is much variability in the generalizability of AETs, although, in general, subjects treated in AETs represent only a minority of patients treated for MDD in a community-based psychiatry outpatient practice.

Entities:  

Mesh:

Year:  2004        PMID: 14770052     DOI: 10.1097/01.nmd.0000110279.23893.82

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  14 in total

1.  Generalizability of clinical trials for cannabis dependence to community samples.

Authors:  Mayumi Okuda; Deborah S Hasin; Mark Olfson; Sharaf S Khan; Edward V Nunes; Ivan Montoya; Shang-Min Liu; Bridget F Grant; Carlos Blanco
Journal:  Drug Alcohol Depend       Date:  2010-05-26       Impact factor: 4.492

2.  Behavior analysis in the era of medicalization: the state of the science and recommendations for practitioners.

Authors:  W Joseph Wyatt
Journal:  Behav Anal Pract       Date:  2009

Review 3.  Eligibility criteria in knee osteoarthritis clinical trials: systematic review.

Authors:  Yun Hyung Koog; Hyungsun Wi; Won Young Jung
Journal:  Clin Rheumatol       Date:  2013-07-23       Impact factor: 2.980

4.  Visual aggregate analysis of eligibility features of clinical trials.

Authors:  Zhe He; Simona Carini; Ida Sim; Chunhua Weng
Journal:  J Biomed Inform       Date:  2015-01-20       Impact factor: 6.317

5.  Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures.

Authors:  W C LaFrance; G I Keitner; G D Papandonatos; A S Blum; J T Machan; C E Ryan; I W Miller
Journal:  Neurology       Date:  2010-08-25       Impact factor: 9.910

6.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.

Authors:  Kelly Posner; Gregory K Brown; Barbara Stanley; David A Brent; Kseniya V Yershova; Maria A Oquendo; Glenn W Currier; Glenn A Melvin; Laurence Greenhill; Sa Shen; J John Mann
Journal:  Am J Psychiatry       Date:  2011-12       Impact factor: 18.112

7.  A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV.

Authors:  Alexander C Tsai; Sheri D Weiser; Maya L Petersen; Kathleen Ragland; Margot B Kushel; David R Bangsberg
Journal:  Arch Gen Psychiatry       Date:  2010-12

8.  Assessing Suicidal Ideation and Behaviors Among Survivors of Childhood Brain Tumors and Their Mothers During Sociobehavioral Research.

Authors:  Matthew S Lucas; Bridgette M Brawner; Thomas L Hardie; Barbara Beacham; Cynthia Paidipati; Magdaline Diaz; Amy Lauer; Wendy L Hobbie; Janet A Deatrick
Journal:  Oncol Nurs Forum       Date:  2015-09       Impact factor: 2.172

9.  The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years.

Authors:  Mark Zimmerman; Carolina Guzman Holst; Heather L Clark; Matthew Multach; Emily Walsh; Lia K Rosenstein; Douglas Gazarian
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

10.  The use of propensity scores and observational data to estimate randomized controlled trial generalizability bias.

Authors:  Taylor R Pressler; Eloise E Kaizar
Journal:  Stat Med       Date:  2013-04-01       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.